Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Anliker

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Antimicrobial Agents and Chemotherapy|August 26, 2009
Pulmonary epithelial lining fluid concentrations after use of systemic amphotericin B lipid formulationsStefan Weiler, Gerda Falkensammer, Angelika Hammerer-Lercher, et al.
Transfusion|October 28, 2018
Complement activation by human red blood cell antibodies: hemolytic potential of antibodies and efficacy of complement inhibitors assessed by a sensitive flow cytometric assayMarkus Anliker, Christoph Q Schmidt, Markus J Harder, et al.
Transfusion|January 4, 2014
A new blood group antigen is defined by anti-CD59, detected in a CD59-deficient patientMarkus Anliker, Inge von Zabern, Britta Höchsmann, et al.
Frontiers in Immunology|August 6, 2019
Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH PatientsMarkus J Harder, Britta Höchsmann, Arthur Dopler, et al.
Clinical Chemistry and Laboratory Medicine|July 4, 2023
Serum sPD-L1 levels are elevated in patients with viral diseases, bacterial sepsis or in patients with impaired renal function compared to healthy blood donorsLorin Loacker, Alexander Egger, Vilmos Fux, et al.
Journal of Clinical Virology Plus|March 9, 2022
Borderline and weakly positive antibody levels against the S-protein of SARS-CoV-2 exhibit limited agreement with virus neutralization titresAlexander E Egger, Christian Irsara, Barbara Holzer, et al.
Frontiers in Endocrinology|July 6, 2021
Testosterone Deficiency Is a Risk Factor for Severe COVID-19Lukas Lanser, Francesco Robert Burkert, Lis Thommes, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 9, 2015
Comparative Analysis of Novel Complement-Targeted Inhibitors, MiniFH, and the Natural Regulators Factor H and Factor H-like Protein 1 Reveal Functional Determinants of Complement RegulationMarkus J Harder, Markus Anliker, Britta Höchsmann, et al.
Blood|December 29, 2016
Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activationMarkus J Harder, Nadine Kuhn, Hubert Schrezenmeier, et al.
Atherosclerosis|July 1, 2020
Impact of lifestyle and cardiovascular risk factors on early atherosclerosis in a large cohort of healthy adolescents: The Early Vascular Ageing (EVA)-Tyrol StudyAnna Staudt, Katharina Stock, Nina Gande, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Antimicrobial Agents and Chemotherapy|August 26, 2009
Pulmonary epithelial lining fluid concentrations after use of systemic amphotericin B lipid formulationsStefan Weiler, Gerda Falkensammer, Angelika Hammerer-Lercher, et al.
Transfusion|October 28, 2018
Complement activation by human red blood cell antibodies: hemolytic potential of antibodies and efficacy of complement inhibitors assessed by a sensitive flow cytometric assayMarkus Anliker, Christoph Q Schmidt, Markus J Harder, et al.
Transfusion|January 4, 2014
A new blood group antigen is defined by anti-CD59, detected in a CD59-deficient patientMarkus Anliker, Inge von Zabern, Britta Höchsmann, et al.
Frontiers in Immunology|August 6, 2019
Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH PatientsMarkus J Harder, Britta Höchsmann, Arthur Dopler, et al.
Clinical Chemistry and Laboratory Medicine|July 4, 2023
Serum sPD-L1 levels are elevated in patients with viral diseases, bacterial sepsis or in patients with impaired renal function compared to healthy blood donorsLorin Loacker, Alexander Egger, Vilmos Fux, et al.
Journal of Clinical Virology Plus|March 9, 2022
Borderline and weakly positive antibody levels against the S-protein of SARS-CoV-2 exhibit limited agreement with virus neutralization titresAlexander E Egger, Christian Irsara, Barbara Holzer, et al.
Frontiers in Endocrinology|July 6, 2021
Testosterone Deficiency Is a Risk Factor for Severe COVID-19Lukas Lanser, Francesco Robert Burkert, Lis Thommes, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 9, 2015
Comparative Analysis of Novel Complement-Targeted Inhibitors, MiniFH, and the Natural Regulators Factor H and Factor H-like Protein 1 Reveal Functional Determinants of Complement RegulationMarkus J Harder, Markus Anliker, Britta Höchsmann, et al.
Blood|December 29, 2016
Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activationMarkus J Harder, Nadine Kuhn, Hubert Schrezenmeier, et al.
Atherosclerosis|July 1, 2020
Impact of lifestyle and cardiovascular risk factors on early atherosclerosis in a large cohort of healthy adolescents: The Early Vascular Ageing (EVA)-Tyrol StudyAnna Staudt, Katharina Stock, Nina Gande, et al.
Pageof 4